News | November 10, 2024
Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Subscribe To Our Newsletter & Stay Updated
